Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study ...

TOPLINE: Glucarpidase treatment in patients with methotrexate-associated acute kidney injury is linked to 2.7 times higher odds of kidney recovery and faster recovery time. The enzyme also reduces ...

Glucarpidase converts MTX in the blood into inactive metabolites within 15 minutes of its administration. Despite its potent biochemical effects, no study has examined whether these effects ...

Treatment with glucarpidase was associated with a 2.7-fold increase in the odds of kidney recovery compared with no glucarpidase treatment (adjusted OR 2.70, 95% CI 1.69-4.31) in data from ...

Glucarpidase treatment significantly improves kidney recovery odds and reduces risks of neutropenia and transaminitis in MTX-AKI patients. The study utilized a target trial emulation framework to ...

Glucarpidase receipt within 4 days of MTX initiation was significantly associated with 2.7-fold increased odds of kidney recovery without dialysis dependence at hospital discharge compared with ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by ...

Researchers built an economic model comparing the current standard of care, including delayed glucarpidase treatment or hemodialysis, with a proposed practice of treating all eligible patients ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the ...

Patients receiving glucarpidase had higher adjusted odds of kidney recovery, shorter time to kidney recovery, and a lower mortality rate.West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE ...

West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX ...

West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX ...